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Abstract 
Introduction: Recent data has demonstrated that hypoxia drives an immunosuppressive tumour microenvironment 
(TME) via various mechanisms including hypoxia inducible factor (HIF)-dependent upregulation of programmed 
death ligand 1 (PD-L1). Both hypoxia and an immunosuppressive TME are targetable independent negative prognos-
tic factors for bladder cancer. Therefore we sought to investigate whether hypoxia is associated with upregulation of 
PD-L1 in the disease.
Materials and methods: Three human muscle-invasive bladder cancer cell lines (T24, J82, UMUC3) were cultured 
in normoxia (20% oxygen) or hypoxia (1 and 0.1% oxygen) for 24 h. Differences in PD-L1 expression were measured 
using Western blotting, quantitative polymerase chain reaction (qPCR) and flow cytometry (≥3 independent experi-
ments). Statistical tests performed were unpaired t tests and ANOVA. For in silico work an hypoxia signature was used 
to apply hypoxia scores to muscle-invasive bladder cancers from a clinical trial (BCON; n = 142) and TCGA (n = 404). 
Analyses were carried out using R and RStudio and statistical tests performed were linear models and one-way 
ANOVA.
Results: When T24 cells were seeded at < 70% confluence, there was decreased PD-L1 protein (p = 0.009) and mRNA 
(p < 0.001) expression after culture in 0.1% oxygen. PD-L1 protein expression decreased in both 0.1% oxygen and 1% 
oxygen in a panel of muscle-invasive bladder cancer cells: T24 (p = 0.009 and 0.001), J82 (p = 0.008 and 0.013) and 
UMUC3 (p = 0.003 and 0.289). Increasing seeding density decreased PD-L1 protein (p < 0.001) and mRNA (p = 0.001) 
expression in T24 cells grown in both 20 and 1% oxygen. Only when cells were 100% confluent, were PD-L1 protein 
and mRNA levels higher in 1% versus 20% oxygen (p = 0.056 and p = 0.037). In silico analyses showed a positive 
correlation between hypoxia signature scores and PD-L1 expression in both BCON (p = 0.003) and TCGA (p < 0.001) 
cohorts, and between hypoxia and IFNγ signature scores (p < 0.001 for both).
Conclusion: Tumour hypoxia correlates with increased PD-L1 expression in patient derived bladder cancer tumours. 
In vitro PD-L1 expression was affected by cell density and decreased PD-L1 expression was observed after culture in 
hypoxia in muscle-invasive bladder cancer cell lines. As cell density has such an important effect on PD-L1 expression, 
it should be considered when investigating PD-L1 expression in vitro.
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Introduction
Bladder cancer is the tenth most common cause of can-
cer death in the UK with an overall 10-year survival rate 
of only 46% in England [1]. Stages two, three and four 
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are classified as muscle-invasive bladder cancer (MIBC) 
for which the five-year survival rates are 45, 40 and 10% 
respectively [2].
The two definitive treatment approaches for MIBC are 
cystectomy, or radiotherapy with a radiosensitiser. Neo-
adjuvant chemotherapy can be given with either, but has 
a limited contribution to improved survival [3]. Immuno-
therapy for bladder cancer has an extensive history, with 
the first immunotherapy (Bacillus Calmette–Guérin) for 
non-MIBC being approved in 1990 [4]. In the last 5 years, 
six new immunotherapies were approved for advanced 
urothelial carcinoma, most targeting the PD-1/PD-L1 
pathway. However, despite initial successes the rates of 
durable responses remain low with generally only around 
one in five patients showing a sustained response [5].
An immunosuppressive tumour microenvironment 
(TME) is known to be a negative prognostic factor con-
tributing to recurrence of disease and tumour progres-
sion [6]. Hypoxia is a common feature of many solid 
tumours and is also an adverse prognostic factor in blad-
der cancer [7, 8]. Both an immunosuppressive TME and 
hypoxia contribute to the failure of radiotherapy [9, 10]. 
Therefore, the relationship between immunosuppression 
and hypoxia is of interest when developing biomarkers to 
guide the management of bladder cancer.
Hypoxia inducible factor (HIF1)-1α is a transcrip-
tion factor that regulates a plethora of genes in response 
to decreased oxygen availability [11]. Recently, it was 
shown that hypoxia-induced gene changes affect tumour 
immune responses and contribute towards an immuno-
suppressive TME [12]. The mechanisms involved include 
direct effects on immune cells that alter their func-
tions and indirect effects due to altered cytokine and 
chemokine expression that impact the recruitment and 
migration of immune cells [13, 14].
Specifically, hypoxia via HIF1α was shown to increase 
expression of the immune checkpoint gene programmed 
death - ligand 1 (PD-L1) in human and mouse cancer cell 
lines [15, 16]. The effect of hypoxia on PD-L1 expression 
in bladder cancer cells has not previously been reported.
Here we aimed to investigate the effects of hypoxia on 




Human MIBC cell lines (T24, J82, UMUC3) were cul-
tured in Eagle’s Minimum Essential Media (Gibco; Ther-
moFisher Scientific, Loughborough, UK) supplemented 
with 10% foetal bovine serum (Gibco) and L-glutamine 
(2 mM; Gibco). Cell lines were authenticated by the Can-
cer Research UK Manchester Institute core facilities ser-
vices every 6 months and tested for mycoplasma monthly.
Exposure to hypoxia
Cells were seeded at a density of 1 ×  105 per well, 
unless otherwise stated, onto 6-well cell culture plates 
(Corning™ Costar™, Leicestershire, UK) in a humidi-
fied atmosphere of air plus 5%  CO2 (here termed nor-
moxia) and left to adhere for 24 h. Some plates were 
then transferred to a hypoxia cabinet (Baker-Russkin®, 
Bridgend, Wales), washed with phosphate buffered 
saline (PBS; made by in-house services) and fresh 
media added. Both the PBS and fresh media were pre-
equilibrated to the required oxygen concentration for 
24 h. The other plates were processed in the same way 
but in normoxia.
Treating cells with pharmacological agents
Human recombinant interferon gamma (IFNγ) (Pepro-
tech, London, UK) was reconstituted in dimethyl sul-
phoxide (DMSO) to make a working stock solution of 
20 μg/ml. It was added directly to media culture at the 
same point of processing as described above to a work-
ing concentration of 10 ng/ml.
Western blotting
Cells were lysed in  situ by adding lysis buffer solution 
(Cell Signalling Technology, London, UK) and pro-
tease inhibitor cocktail (Cell Signalling Technology) 
and placing on ice for 10 min. Samples were then soni-
cated at 10 amplitude microns for 10 s using a Soniprep 
150 (Measuring and Scientific Equipment, London, 
UK) before centrifugation at 14,000 G for 15 min. 
Protein concentrations of the lysates were measured 
using a BCA Protein Assay kit (ThermoFisher Scien-
tific, Loughborough, UK), and the solution resolved on 
4–20% Tris-Glycine Protein Gels (ThermoFisher Scien-
tific) prior to transferring to a nitrocellulose membrane 
(Bio-Rad, Watford, UK). The membrane was then incu-
bated with the primary and secondary antibodies with 
PBS washes in between. Table 1 lists antibody suppliers 
and concentrations.
Table 1 Concentrations and supplier information of antibodies 
used for Western blotting
Target Raised in Dilution Supplier Code
PD-L1 Rabbit 1:2000 Cell Signalling Technology 13,684
HIF1α Mouse 1:500 BD 610,959
GAPDH Rabbit 1:2500 Cell Signalling Technology 2118
Mouse-HRP Goat 1:7500 Invitrogen 62–6520
Rabbit-HRP Goat 1:5000 Invitrogen 65–6120
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Real‑time PCR
RNA was extracted using a Qiagen RNeasy Mini Kit 
according to the manufacturer’s protocol and quanti-
fied using a NanoDrop™ (ThermoFisher Scientific). 
cDNA was obtained using OmniScript RT Kit (Qiagen, 
Manchester, UK) with random hexamer primers (Ther-
moFisher Scientific) and RNase Inhibitor (New England 
Biolabs, Hitchin, UK). Primers were designed by Primer-
BLAST and Primer3 software, checked using Beacon 
Design Software (Premier Biosoft) and made by Eurofins 
Genomics (Ebersberg, Germany) before being resus-
pended in Tris – EDTA (TE) buffer. Table 2 lists primer 
sequences. Serial dilutions of primers were used for vali-
dation experiments and primer mixes were made with 
SYBR Green Master Mix (ThermoFisher Scientific). 384-
well PCR plates were run using a QuantStudio 5 Real-
Time PCR System and appropriate controls.
Flow cytometry
Cells were trypsinised, placed in fluorescence-activated 
cell sorting (FACS) tubes (Corning, Flintshire, UK), 
washed in FACS buffer (1% FBS in PBS), centrifuged and 
resuspended in a series of solutions with FACS buffer 
washing steps in between. In order, the cells were resus-
pended in a live/dead fixable cell stain (1:1000; Invitrogen; 
ThermoFisher Scientific), human FcR blocking solu-
tion (1:100; Miltenyi Biotec, Woking, UK), then either 
PD-L1 PE antibody (1:100; Invitrogen) or control PE 
mouse IgG1 k isotype antibody (1:100) (BD Pharmigen, 
CA, USA) before being fixed in 1% paraformaldehyde. 
Samples were acquired on a LSRII flow cytometer (BD 
Biosciences, CA, USA) with 10,000 viable cells collected 
per sample. Flow cytometry was performed in either 
duplicate or triplicate wells as stated and each well was 
split into two FACS tubes for immunoglobulin control 
alongside target of interest. The data collected were then 
processed using FlowJo software (version 10.6.1). Table 3 
lists reagent details.
Bioinformatics
BCON is a clinical trial registered as CRUK/01/003 of 
which the details and conclusions are outlined in the ini-
tial findings report [17]. Gene expression data from the 
BCON cohort were obtained as previously described 
[18] and the TCGA-BLCA data were obtained using the 
R packages “TCGAUtils” and “curatedTCGAData”. Both 
datasets were filtered to include only tumours of a known 
stage and stage 2 and above. Analyses were carried out 
using R (version 4.0.3) and RStudio (version 1.3).
Statistical analysis
In vitro data were tested by unpaired t test or ANOVA 
using GraphPad Prism 8 software. In silico data were 
tested by linear regression, Pearson’s correlation and 
ANOVA using R and RStudio.
Results
Hypoxia decreases expression of PD‑L1 in T24 human 
bladder cancer cells
To investigate the effects of hypoxia on PD-L1 expres-
sion in T24 MIBC cells they were cultured at 0.1% oxygen 
and 20% oxygen and the differences in PD-L1 expression 
examined. PD-L1 expression significantly decreased in 
hypoxia (0.1% oxygen for 24 h) at both the RNA (qPCR) 
and protein (Western blotting, flow cytometry) level in 
T24 human bladder cancer cells (Fig. 1). IFNγ is a known 
stimulant of PD-L1 and its addition led to the expected 
stimulation of PD-L1 [19]. However, when IFNγ stimu-
lated cells were cultured in hypoxia, the IFNγ-driven 
PD-L1 increase was reduced (Fig.  1). This finding fur-
ther highlights the negating effects of hypoxia on PD-L1 
expression in T24 cells. HIF1α protein expression was 
present in all the samples cultured in hypoxia (0.1% oxy-
gen) and absent in those under normoxia, confirming the 
cells are responding to the hypoxic conditions (Supple-
mentary Fig. 1). Comparison of the proportion of viable 
Table 2 Primer sequences and their properties used for qPCR
Primer Sequence Tm (°C) GC‑content (%)
PD-L1 forward TAT GGT GGT GCC GAC TAC AA 57.3 50
PD-L1 reverse TGG CTC CCA GAA TTA CCA AG 57.3 50
SDHA forward CAT CCA CTA CAT GAC GGA 
GCA 
59.8 52.4
SDHA reverse ATC TTG CCA TCT TCA GTT 
CTG CTA 
59.3 41.7
Table 3 Concentrations and supplier details of reagents used for flow cytometry
Name Details Dilution Supplier Code
Live/dead stain Diluted in PBS 1:1000 Invitrogen L34973
Fc blocking Diluted in FACs buffer 1:100 Miltenyi Biotec 130–059-901
PD-L1 antibody PE conjugated 1:100 Fisher Scientific 12–5983-41
IgG antibody PE conjugated 1:100 BD Pharmigen 554,121
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cells between samples showed hypoxia did not induce 
excessive cell death (Supplementary Fig. 2).
Both 0.1 and 1% hypoxia decreases PD‑L1 expression 
in a panel of human muscle‑invasive bladder cancer cells
To investigate whether the decrease in PD-L1 might 
be cell line or oxygen concentration dependent, we 
investigated two other human MIBC cell lines (J82 and 
UMUC3) and a less severe level of hypoxia (1% oxygen). 
There was a consistent significant decrease in PD-L1 
protein expression after exposure to hypoxia in all three 
bladder cancer cell lines and at both 0.1 and 1% oxygen 
concentrations (Fig. 2). Across the three cell lines there 
was also a continued attenuation of the IFNγ-driven 
PD-L1 induction in hypoxia.
Fig. 1 Hypoxia (0.1%) decreases the expression of PD-L1 in T24 bladder cancer cells. PD-L1 expression decreased in T24 cells after 24 h culture in 
0.1% oxygen. IFNγ stimulation increased expression of PD-L1 in 20%  O2, but the IFNγ-driven increase was attenuated in cells grown in 0.1%  O2. 
Cells were seeded and left to adhere for 24 h before placing into a hypoxia chamber for 24 h and/or 10 ng/ml IFNγ added to the culture media. 
A) Western blotting shows the change in protein levels of PD-L1 with GAPDH used as a loading control. Three independent experiments were 
carried out and a representative image is shown. B) Quantification by densitometry analysis was performed using ImageJ by calculating the relative 
densities of both the loading control and the samples to the control untreated lane. These values were then scaled to the relative density values 
to find adjusted relative values from three independent experiments. C) Flow cytometry shows the change in surface expression of PD-L1. Data 
are the mean ± standard error of the mean (SEM) of the mean fluorescence intensity of 10,000 viable cells from replicates of four independent 
experiments normalised to normoxia untreated condition to show the relative fold change. D) qPCR shows changes in mRNA levels relative to the 
mRNA levels of T24 cells cultured in 20%  O2. Data are the mean ± standard error of the mean (SEM) from three independent experiments plated 
in triplicate with differences calculated using the delta-delta Ct method relative to the expression of reference gene SDHA. Statistical tests are 
unpaired t tests performed in GraphPad Prism with p values represented as follows: ns = not significant, * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001
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PD‑L1 levels decrease as cell density increases and a PD‑L1 
increase in hypoxia occurs only when cells are highly 
confluent
The effects of cell density on hypoxia-induced changes 
in PD-L1 expression were explored in T24 cells. This 
cell line was used due to its fast proliferation rate, with 
a doubling time of around 20 h [20, 21], which facilitated 
the assessment of increasing cell density. As we showed 
similar effects in both 0.1 and 1% hypoxia we took for-
ward the less severe 1% hypoxia for further experi-
ments to minimise stress on the cells. Density gradient 
experiments showed PD-L1 protein and mRNA expres-
sion decreased significantly with increasing cell den-
sity in both normoxia and hypoxia (Fig. 3). A significant 
hypoxia-induced increase in PD-L1 expression was only 
seen when the cells were seeded at the highest densities 
(Fig. 3). Increasing cell density had no effect on viability 
(Supplementary Fig. 3).
PD‑L1 gene expression correlates positively with hypoxia 
in muscle‑invasive bladder cancer patients
To elucidate further the potential relationship and clini-
cal relevance between hypoxia and PD-L1, in silico 
analyses were performed using gene expression data-
sets from two bladder cancer cohorts. A bladder can-
cer specific hypoxia signature previously published was 
used to assign hypoxia scores, which were then corre-
lated with the expression of PD-L1 (CD274) [18]. A sig-
nificant positive correlation was seen between hypoxia 
signature scores and the expression of PD-L1 in both 
cohorts (Fig.  4A, B). The median hypoxic score across 
each cohort stratified patients into low and high hypoxia 
groups. In both cohorts, the high hypoxia tumours had a 
significantly higher expression of PD-L1 compared with 
low hypoxia tumours (Fig. 4C, D).
Hypoxia and IFNγ‑signalling signature scores correlate 
positively in muscle‑invasive bladder cancer patients
Finally, a published IFNγ gene signature represent-
ing extent of IFNγ signalling was used to attribute IFNγ 
scores to the BCON and TCGA cohorts [22]. There were 
positive correlations between hypoxia and IFNγ signa-
ture scores (Fig. 5A, B). The tumours were again stratified 
into low and high hypoxia and in both cohorts the high 
hypoxia tumours showed significantly higher IFNγ scores 
compared with the low hypoxia tumours (Fig. 5C, D).
Discussion
Several findings emerged from this study. First, hypoxia 
decreased PD-L1 expression and abrogated IFNγ-
induced increases in PD-L1 in bladder cancer cells. Sec-
ond, PD-L1 expression decreased with increasing cell 
seeding density, which was pronounced in cells cultured 
in normoxia versus hypoxia. Third, a hypoxia-induced 
increase in PD-L1 was only seen with the highest cell 
seeding densities when there was a marked down-regula-
tion of PD-L1 in cells grown in normoxia. Fourth, PD-L1 
gene expression, as well as IFNγ-signalling expression, 
correlated positively with hypoxia in bladder cancers in 
silico.
The observation that hypoxia decreases PD-L1 expres-
sion initially appears to conflict with conclusions made 
in published literature. Noman et al. [16] concluded that 
hypoxia induced an upregulation of PD-L1 in a panel 
of murine and human cell lines. However, the finding 
appears to be tissue-type specific as only one (B16-F10) 
of four murine cell lines (B16-F10 melanoma; LLC lung; 
CT26 colon; 4 T1 mammary) studied showed an increase 
in the percentage of PD-L1 positive cells after culture 
in 0.1% oxygen. There was a minimal increase at 72 h in 
the lung, no change in the colon, and a non-significant 
decrease in the mammary cell line. In the human cell 
lines, there was a marked hypoxia-induced increase 
in PD-L1 in melanoma (T1, M4T), a small significant 
increase in lung (IGR-Heu), and no change in breast 
(MCF-7). In addition, all the hypoxia results (24 h, 48 h, 
72 h) were compared with 72 h normoxia data. Inter-
estingly, across the cell lines, there were no significant 
changes observed at 24 h, except for the murine mela-
noma cell line, and most of the significant changes were 
seen at the 72 h time-point. As cell density will increase 
at the later time-point, the results might be affected by 
the cell density effect we found here.
Barsoum et  al. [15] also reported hypoxia-induced 
upregulation of PD-L1 expression. They incubated 
cells in 0.5% oxygen for 24 h and showed an increase in 
PD-L1 expression in human prostate (DU145) and breast 
(MDA-MB-231) cancer cells. The authors stated that all 
their experiments were conducted using cultures that did 
(See figure on next page.)
Fig. 2 Hypoxia (0.1 and 1%) decreases PD-L1 expression in a panel of human bladder cancer cells. Flow cytometry analyses show the surface 
expression of PD-L1 decreases after culture in hypoxia across a panel of human bladder cancer cells. Culture in 0.1 and 1%  O2 for 24 h decreases 
the expression of PD-L1 compared with the levels present when cultured under 20%  O2 in T24 (A), J82 (B), UMUC3 (C) bladder cancer cells. Cells 
were seeded and left to adhere for 24 h before placing in 0.1% or 1%  O2 for 24 h and 10 ng/mL IFNγ added to the relevant wells. Data are the 
mean ± standard error of the mean (SEM) of the mean fluorescence intensity of 10,000 viable cells from replicates of at least two independent 
experiments normalised to the normoxia untreated condition to show the relative fold change. Statistical tests are unpaired t tests performed in 
GraphPad Prism with p values represented as follows: ns = not significant, * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001
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not exceed 70% confluence. The study also used siRNA 
knockdown experiments to show that PD-L1 upregula-
tion was HIF1α dependent. HIFs bind to gene promoter 
regions known as hypoxia response elements (HREs). In 
2011, Schödel et  al. used chromatin immunoprecipita-
tion sequencing (ChIPseq) to perform high resolution 
mapping of HIF binding sites in MCF-7 cells; PD-L1 was 
not in their 300+ list of high stringency HIF1 and HIF2 
binding sites [23]. Given that Noman et  al. also saw no 
effect of hypoxia on the expression of PD-L1 in MCF-7 
cells, but Barsoum et  al. identified HREs in the PD-L1 
gene in DU145 cell lines as well as an hypoxia-induced 
increase in PD-L1 expression, it is possible that the 
hypoxia-induced upregulation of PD-L1 is tissue specific 
[15, 16]. To our knowledge this is the first documentation 
of the effects of hypoxia on PD-L1 expression in bladder 
cancer cell lines. The current literature outlines a discrep-
ancy between the effects of hypoxia on the expression 
of PD-L1 across cell lines of different tissue origins and 
further comprehensive characterisation across an exten-
sive panel of other cancer cell lines is required for more 
definitive conclusions.
Hypoxic cells preserve energy by reducing meta-
bolic processes via HIF regulation of various genes [11]. 
Decreases in cellular metabolism also occur as a result of 
increasing cell density, and a recently published report 
underlines the importance of considering cell density 
in in vitro experiments and how cell density affects cel-
lular metabolic changes [24, 25]. Therefore, the PD-L1 
decrease we found in cells cultured in hypoxia could 
be due to reduced cellular metabolism. Furthermore, 
cells proliferate faster in normoxia than in hypoxia due 
to having higher cellular metabolism. Therefore, in the 
highly dense cells, a cell density-mediated reduction in 
metabolism should occur faster and be more pronounced 
in normoxia. The observed effect, therefore, might be 
an abrogated decreased PD-L1 expression occurring 
in the densely packed hypoxic conditions, rather than a 
true cellular hypoxia-driven increase and warrants fur-
ther investigation. In support of this suggestion, several 
publications showed that increasing cell density results 
in decreased expression of cell surface markers includ-
ing transforming growth factor beta (TGF-b) receptor 
in fibroblast cells, epidermal growth factor receptors 
(EGFRs) in breast cancer cells, and tumour necrosis 
factor (TNF) receptors in HeLa epithelial and myeloid 
HL-60 cell lines [26–28].
Increasing cell density leads to contact inhibition and 
cell cycle arrest via the Hippo/YAP pathway [29], and 
interacts with multiple intracellular signalling pathways 
Fig. 3 PD-L1 expression decreases with increasing cell density and hypoxia-induced PD-L1 increase occurs only in high-density cells. As T24 
cell seeding density increases, the protein and mRNA expression of PD-L1 decrease in both normoxia and hypoxia conditions (p < 0.001 and 
p = 0.0011 respectively). When the cells are cultured at higher densities (100% confluence) PD-L1 protein and mRNA expression increases after 
culture in hypoxia compared with normoxia (p = 0.05576 and p = 0.03721 respectively). Cells were counted and seeded into six-well plates at 
different densities, left to adhere for 24 h and then incubated for 24 h. A) Flow cytometry shows the change in surface expression of PD-L1. Data 
are the mean ± standard error of the mean (SEM) of the mean fluorescence intensity of 10,000 viable cells from replicates of three independent 
experiments normalised to normoxia untreated condition to show the relative fold change. B) qPCR shows changes in mRNA levels relative to 
the mRNA levels of T24 cells cultured in a 20%  O2 incubator. Data are the mean ± standard error of the mean (SEM) from three independent 
experiments plated in triplicate and the difference calculated using the delta-delta Ct method relative to the expression of reference gene SDHA. 
Statistical tests are linear models and ANOVA performed using R and RStudio with p values represented as follows: ns = not significant, * < 0.05, 
** < 0.01, *** < 0.001, **** < 0.0001
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[30–32] that regulate cyclin D expression [33]. PD-L1 
expression is also affected directly by the cell cycle via 
cyclin D regulation [34] and via interactions with multiple 
cell signalling pathways, e.g., via PI3K/AKT, JAK/STAT3, 
WNT, NFkB and MAPK [35, 36]. This complex inter-
play between cell density, cell cycle, cell signalling and 
PD-L1 expression is yet to be fully elucidated and more 
research is needed to understand how hypoxia affects the 
interactions. Although we showed cell density affects the 
expression of PD-L1, we have not identified whether it is 
a direct effect, or due to cell density-mediated changes in 
cell cycle or cell signalling. The discrepancy in some of 
the in vitro results could potentially be explained by fur-
ther investigations into the cell cycle and cell signalling 
pathways to determine how these affect the changes in 
PD-L1 expression in response to hypoxia.
To further explore the relationship between hypoxia 
and PD-L1 beyond the in vitro cell culture experiments 
we performed in silico analyses in patient tumours. The 
BCON trial randomised patients to receive either radio-
therapy or radiotherapy plus hypoxia-modifying carbo-
gen and nicotinamide (CON). TCGA-BLCA is a cohort 
Fig. 4 In silico analyses show a positive association between hypoxia and PD-L1 in muscle-invasive bladder tumours. Analyses involved microarray 
data from the BCON trial normalised previously using aroma package and filtered to include only tumours stage 2 and above (n = 142) and the 
TCGA-BLCA RNASeq2GeneNorm dataset downloaded using the Bioconductor package TCGAutils and filtered to include only tumours of a known 
stage 2 and above (n = 404). Hypoxia scores were applied to each tumour sample using a previously published 24-gene bladder cancer hypoxia 
signature. Hypoxia signature scores were plotted against the expression of PD-L1 in A) BCON and C) TCGA cohorts.  R2 values were calculated 
using Pearson’s correlation coefficient and the p values represent a linear model analysis. Tumours were stratified into hypoxia low or high using 
the median of the hypoxia scores for each cohort, and plotted against the PD-L1 expression in the B) BCON and D) TCGA cohorts. P values were 
calculated using one way ANOVA between the two groups. p values are represented as follows: ns = not significant, * < 0.05, ** < 0.01, *** < 0.001, 
**** < 0.0001
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of bladder cancer patients who underwent surgery and 
the gene expression dataset from these tumours is pub-
licly available. The positive correlations seen between 
hypoxia signature scores and PD-L1 expression in both 
cohorts indicates that, despite our cell line findings, 
there is a relationship between the extent of hypoxia 
and increased PD-L1 expression in bladder cancer. This 
has implications for the treatment of MIBC whereby 
some patients may potentially benefit from a combina-
tion of hypoxia-modifying therapy with immunotherapy 
agents. In the same cohorts, we saw a positive correla-
tion between hypoxia and IFNγ-signalling signature 
scores. IFNγ is known to stimulate PD-L1 and increased 
PD-L1 expression in the more hypoxic tumours could be 
a direct result of increased IFNy signalling [19]. Current 
in silico investigations have shown more immune infil-
trates present as tumour hypoxia increases. As IFNγ is a 
central immune signalling molecule that is produced by 
many immune infiltrates, this provides an explanation 
for the increased IFNγ-signalling in the more hypoxic 
tumours. This suggestion needs investigating further. 
Taken together, our in  vitro and in silico findings show 
that, although hypoxia-mediated cellular PD-L1 upregu-
lation is not seen in bladder cancer cell lines, there is an 
overall increased expression of PD-L1 as tumour hypoxia 
increases in bladder cancer, which could be a result of 
Fig. 5 In silico analyses show a positive association between hypoxia and IFNγ-signalling in muscle-invasive bladder tumours. Hypoxia scores were 
applied to tumours from BCON and TCGA cohorts filtered to include stage 2 and above only. A published 6-gene IFNγ gene signature was used to 
attribute an IFNγ score to each tumour. These scores were plotted against the hypoxia scores in the A) BCON and C) TCGA cohorts.  R2 values were 
calculated using Pearson’s correlation coefficient and the p values represent a linear model analysis. Tumours were stratified into hypoxia low or 
high using the median of the hypoxia score from each cohort, and plotted against the IFNγ signature score in the B) BCON and D) TCGA cohorts. P 
values were calculated using one way ANOVA between the two groups. p values are represented as follows: ns = not significant, * < 0.05, ** < 0.01, 
*** < 0.001, **** < 0.0001
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increased IFNγ-signalling in the more hypoxic TMEs 
leading to an increased PD-L1 expression. These results 
highlight the importance of including patient sam-
ple analysis alongside cell line work when investigating 
immune-related contexts to provide translatable findings 
that account for the immune tumour microenvironment.
Conclusions
In conclusion, we report for the first time that in blad-
der cancer cells the in  vitro cell density affects PD-L1 
expression in contrast to an absence of hypoxia-induced 
increase in PD-L1 expression. These findings underlie 
both the importance of cell density on the expression of 
PD-L1 in  vitro and the need to address and document 
this in further publications. Our clinical data provide evi-
dence that hypoxia may induce an immunosuppressive 
TME in bladder cancer and highlight the importance of 
further studies to investigate the underlying mechanisms.
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incorporated into the assay, which only enters cells with compromised 
membranes. Gating around cells with no dye uptake and comparing with 
total population allows for the analysis of the proportion of viable cells. 
Data are the mean ± standard error of the mean (SEM) from at least three 
independent experiments performed in duplicates, of which each sample 
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Additional file 6: Supplementary Figure 6. Full length original and 
unprocessed Western blots shown in Supplementary Fig. 1. Western blot 
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different experimental conditions. GAPDH was used as an experimental 
loading control. Independent experiments were performed at least three 
times and a representative blot is shown.
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